Based on pathological gene-sequencing, patients with BCL2 gene fusion mutation are significantly more likely to have dyslipidemia (chi-square test, 76.5%, p = 0.006) and hypertriglyceridemia (chi-square test, 88.2%, p = 0.002) than patients without rearrangement of these three genes. This evidence concerns the gene BCL2 and metabolic syndrome.